Home › Companies › MYRIAD GENETICS INC. › 2024-2025

MYRIAD GENETICS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and MYRIAD GENETICS INC.’s Form 8-K, filed June 5, 2025 (Item 5.07 on EDGAR). Page generated October 14, 2026.

6Ballot items
247Asset managers
1,732Fund votes
June 5, 2025Meeting date

Results at a glance

Meeting of June 5, 2025: 6 items on MYRIAD GENETICS INC.’s Form 8-K, filed June 5, 2025: 2 approved · 4 without a stated outcome.

Material dissent

None.

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore MYRIAD GENETICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by MYRIAD GENETICS INC.

These tallies are MYRIAD GENETICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 5, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

MYRIAD GENETICS INC. — official shareholder meeting results, meeting held June 5, 2025
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Samraat S. Raha	73,401,449	258,083	23,526	--	8,547,127	99.6%	Not verified	—
Elect Director: Heiner Dreismann, PH.D.	69,560,417	4,098,163	24,478	--	8,547,127	94%	Not verified	—
Elect Director: Colleen F. Reitan	69,922,952	3,732,650	27,456	--	8,547,127	95%	Not verified	—
2. Ratification of the Selection of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2025	78,614,062	3,591,463	24,660	--	--	96%	Approved	—
3. Approval, on an Advisory Basis, of the Compensation of Our Named Executive Officers, as Disclosed in the Proxy Statement	67,755,156	5,847,659	80,243	--	8,547,127	92%	Approved	—
4. Approval of a Proposed Amendment to the 2017 Plan to Replenish the Share Pool for Equity Incentive Grants	69,476,724	4,175,785	30,549	--	8,547,127	94%	Not verified	—

This meeting is also recorded here as June 3, 2025; both records come from the same filing, so the date should be checked against it.

Source: MYRIAD GENETICS INC., Form 8-K, filed with the SEC on June 5, 2025 — read the filing on EDGAR.

How asset managers voted at the MYRIAD GENETICS INC. 2024-2025 meeting

Each item below shows how the 247 asset managers that disclosed a MYRIAD GENETICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Colleen F. Reitan

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 4 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%

FOR: 69,922,952AGAINST: 3,732,650

Details: description as filed, official tally, votes by 67 asset managers

Description as filed by funds: Election of three Class II Directors to serve until the 2028 Annual Meeting of Stockholders: Colleen F. Reitan

MYRIAD GENETICS INC.’s own tally for this item (“Elect Director: Colleen F. Reitan”): 69,922,952 for, 3,732,650 against, per its Form 8-K filed June 5, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 67 asset managers below reported 35,853,262 for, 1,841,754 against, 0 abstained, 64,819 not voted.

FOR

FOR: 35,853,262AGAINST: 1,841,754ABSTAIN: 0NOT VOTED: 64,819

Largest asset managers voting on “Election of three Class II Directors to serve until the 2028 Annual Meeting of Stockholders: Colleen F. Reitan” at MYRIAD GENETICS INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	13,657,059	4,720	For
BlackRock	10,642,000	0	For
State Street	3,216,238	0	For
Fidelity	2,642,110	0	For
Dimensional	1,279,128	0	For
Charles Schwab	1,130,181	0	For
TIAA	0	1,075,090	Against
Invesco	0	656,247	Against
Elevation Series Trust	346,279	0	For
Goldman Sachs	253,198	0	For
Equitable	142,267	96,950	Mixed
Jackson National	182,129	0	For
Columbia Threadneedle	180,059	0	For
JPMorgan	167,057	0	For
Global X	160,433	0	For
Prudential/PGIM	152,976	0	For
QUANTITATIVE MASTER SERIES LLC	150,778	0	For
Lincoln Financial	121,397	0	For
Northern Trust	111,886	0	For
BNY Mellon	98,811	0	For
Thrivent	93,170	0	For
Principal	88,419	0	For
TARGET PORTFOLIO TRUST	84,800	0	For
Voya	72,572	0	For
Direxion Shares ETF Trust	68,584	0	For

Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.

2. Elect Director: Heiner Dreismann, PH.D.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 4 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%

FOR: 69,560,417AGAINST: 4,098,163

Details: description as filed, official tally, votes by 67 asset managers

Description as filed by funds: Election of three Class II Directors to serve until the 2028 Annual Meeting of Stockholders: Heiner Dreismann, Ph.D.

MYRIAD GENETICS INC.’s own tally for this item (“Elect Director: Heiner Dreismann, PH.D.”): 69,560,417 for, 4,098,163 against, per its Form 8-K filed June 5, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 67 asset managers below reported 37,580,503 for, 114,513 against, 0 abstained, 64,819 not voted.

FOR

FOR: 37,580,503AGAINST: 114,513ABSTAIN: 0NOT VOTED: 64,819

Largest asset managers voting on “Election of three Class II Directors to serve until the 2028 Annual Meeting of Stockholders: Heiner Dreismann,” at MYRIAD GENETICS INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	13,661,773	6	For
BlackRock	10,642,000	0	For
State Street	3,216,109	129	For
Fidelity	2,642,110	0	For
Dimensional	1,279,128	0	For
Charles Schwab	1,130,181	0	For
TIAA	1,075,090	0	For
Invesco	656,247	0	For
Elevation Series Trust	346,279	0	For
Goldman Sachs	253,198	0	For
Equitable	142,267	96,950	Mixed
Jackson National	182,129	0	For
Columbia Threadneedle	180,059	0	For
JPMorgan	167,057	0	For
Global X	160,433	0	For
Prudential/PGIM	152,976	0	For
QUANTITATIVE MASTER SERIES LLC	150,778	0	For
Lincoln Financial	121,397	0	For
Northern Trust	111,886	0	For
BNY Mellon	98,811	0	For
Thrivent	93,170	0	For
Principal	88,419	0	For
TARGET PORTFOLIO TRUST	84,800	0	For
Voya	72,572	0	For
Direxion Shares ETF Trust	68,584	0	For

Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.

3. Elect Director: Samraat S. Raha

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 4 wordings of this item as funds reported it.

99.6% Majority: yes · of votes cast

FOR 99.6%

FOR: 73,401,449AGAINST: 258,083

Details: description as filed, official tally, votes by 67 asset managers

Description as filed by funds: Election of three Class II Directors to serve until the 2028 Annual Meeting of Stockholders: Samraat S. Raha

MYRIAD GENETICS INC.’s own tally for this item (“Elect Director: Samraat S. Raha”): 73,401,449 for, 258,083 against, per its Form 8-K filed June 5, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 67 asset managers below reported 37,695,016 for, 0 against, 0 abstained, 64,819 not voted.

FOR

FOR: 37,695,016AGAINST: 0ABSTAIN: 0NOT VOTED: 64,819

Largest asset managers voting on “Election of three Class II Directors to serve until the 2028 Annual Meeting of Stockholders: Samraat S. Raha” at MYRIAD GENETICS INC., 2024-2025
Asset manager	For	Vote
Vanguard	13,661,779	For
BlackRock	10,642,000	For
State Street	3,216,238	For
Fidelity	2,642,110	For
Dimensional	1,279,128	For
Charles Schwab	1,130,181	For
TIAA	1,075,090	For
Invesco	656,247	For
Elevation Series Trust	346,279	For
Goldman Sachs	253,198	For
Equitable	239,217	For
Jackson National	182,129	For
Columbia Threadneedle	180,059	For
JPMorgan	167,057	For
Global X	160,433	For
Prudential/PGIM	152,976	For
QUANTITATIVE MASTER SERIES LLC	150,778	For
Lincoln Financial	121,397	For
Northern Trust	111,886	For
BNY Mellon	98,811	For
Thrivent	93,170	For
Principal	88,419	For
TARGET PORTFOLIO TRUST	84,800	For
Voya	72,572	For
Direxion Shares ETF Trust	68,584	For

Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.

4. 4. Approval of a Proposed Amendment to the 2017 Plan to Replenish the Share Pool for Equity Incentive Grants

Outcome not verifiedCOMPENSATIONReported outcome: Not verified

Combines 2 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%

FOR: 69,476,724AGAINST: 4,175,785

Details: description as filed, official tally, votes by 66 asset managers

Description as filed by funds: TO APPROVE THE PROPOSED AMENDMENT TO THE 2017 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN, AS AMENDED, TO REPLENISH THE SHARE POOL FOR EQUITY INCENTIVE GRANTS.

MYRIAD GENETICS INC.’s own tally for this item (“4. Approval of a Proposed Amendment to the 2017 Plan to Replenish the Share Pool for Equity Incentive Grants”): 69,476,724 for, 4,175,785 against, per its Form 8-K filed June 5, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Also reported under other wordings, matched to the same row of MYRIAD GENETICS INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Amend Restricted Stock Plan” (3 managers, 71 for, 7,900 against, 64,819 not voted).

The 66 asset managers below reported 37,572,061 for, 123,145 against, 0 abstained.

FOR

FOR: 37,572,061AGAINST: 123,145ABSTAIN: 0

Largest asset managers voting on “TO APPROVE THE PROPOSED AMENDMENT TO THE 2017 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN, AS AMEN” at MYRIAD GENETICS INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	13,661,773	6	For
BlackRock	10,642,000	0	For
State Street	3,216,109	129	For
Fidelity	2,642,110	0	For
Dimensional	1,279,128	0	For
Charles Schwab	1,130,181	0	For
TIAA	1,075,090	0	For
Invesco	656,247	0	For
Elevation Series Trust	346,279	0	For
Goldman Sachs	253,198	0	For
Equitable	239,217	0	For
Jackson National	182,129	0	For
Columbia Threadneedle	180,059	0	For
JPMorgan	167,057	0	For
Global X	160,433	0	For
Prudential/PGIM	94,002	58,974	Mixed
QUANTITATIVE MASTER SERIES LLC	150,778	0	For
Lincoln Financial	121,397	0	For
Northern Trust	111,886	0	For
BNY Mellon	98,811	0	For
Thrivent	93,170	0	For
Principal	88,419	0	For
TARGET PORTFOLIO TRUST	84,800	0	For
Voya	72,572	0	For
Direxion Shares ETF Trust	68,584	0	For

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

5. 3. Approval, on an Advisory Basis, of the Compensation of Our Named Executive Officers, as Disclosed in the Proxy…

Official result Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 6 wordings of this item as funds reported it.

92% Approved · of votes cast

FOR 92%

FOR: 67,755,156AGAINST: 5,847,659

Details: description as filed, official tally, votes by 246 asset managers

Description as filed by funds: TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY STATEMENT.

MYRIAD GENETICS INC.’s own tally for this item (“3. Approval, on an Advisory Basis, of the Compensation of Our Named Executive Officers, as Disclosed in the Proxy Statement”): 67,755,156 for, 5,847,659 against — passed, per its Form 8-K filed June 5, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The advisory vote to approve the compensation of the Company's named executive officers, as disclosed in the proxy statement, was approved by stockholders.”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 67 asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY ” at MYRIAD GENETICS INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	13,654,565	7,214	For
BlackRock	10,642,000	0	For
State Street	3,212,568	3,670	For
Fidelity	2,642,110	0	For
Dimensional	1,279,128	0	For
Charles Schwab	1,130,181	0	For
TIAA	1,075,090	0	For
Invesco	656,247	0	For
Elevation Series Trust	0	346,279	Against
Goldman Sachs	253,198	0	For
Equitable	239,217	0	For
Jackson National	182,129	0	For
Columbia Threadneedle	180,059	0	For
JPMorgan	0	167,057	Against
Global X	160,433	0	For
Prudential/PGIM	152,976	0	For
QUANTITATIVE MASTER SERIES LLC	150,778	0	For
Lincoln Financial	121,397	0	For
Northern Trust	111,886	0	For
BNY Mellon	98,811	0	For
Thrivent	93,170	0	For
Principal	88,419	0	For
TARGET PORTFOLIO TRUST	84,800	0	For
Voya	72,572	0	For
Direxion Shares ETF Trust	68,584	0	For

Fund voting reports, all 67 managers: 37,159,260 for, 535,756 against, 0 abstained, 64,819 not voted. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 198 asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY ” at MYRIAD GENETICS INC., 2024-2025
Asset manager	For	Against	Vote
State Street	5,040,773	5,002	For
DISCIPLINED GROWTH INVESTORS INC /MN	0	4,023,596	Against
Wellington	3,792,509	0	For
GLENVIEW CAPITAL MANAGEMENT, LLC	3,720,518	0	For
BlackRock	3,715,866	1,340	For
EARNEST PARTNERS LLC	3,128,254	0	For
DE Shaw	2,402,588	0	For
Camber Capital Management LP	2,350,000	0	For
GEODE CAPITAL MANAGEMENT, LLC	2,239,247	0	For
Charles Schwab	1,185,206	0	For
Nuveen	1,081,085	0	For
Invesco	886,005	0	For
MELLON INVESTMENTS Corp	622,067	0	For
Northern Trust	582,220	0	For
Fisher Asset Management, LLC	577,214	0	For
Portolan Capital Management, LLC	564,709	0	For
Connor, Clark & Lunn Investment Management Ltd.	523,262	0	For
PRINCIPAL GLOBAL INVESTORS	452,847	0	For
Point72	372,108	0	For
BALYASNY ASSET MANAGEMENT L.P.	340,956	0	For
NORDEA INVESTMENT MANAGEMENT AB	0	337,129	Against
Dimensional	318,351	0	For
PUBLIC SECTOR PENSION INVESTMENT BOARD	310,026	0	For
Vanguard	301,277	0	For
JPMorgan	0	213,602	Against

Institutional-manager reports, all 198 managers: 37,854,548 for, 5,092,656 against, 41,139 abstained, 38,348 not voted. Showing the 25 largest; see all in the interactive database.

6. 2. Ratification of the Selection of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

96% Approved · of votes cast

FOR 96%

FOR: 78,614,062AGAINST: 3,591,463

Details: description as filed, official tally, votes by 67 asset managers

Description as filed by funds: TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

MYRIAD GENETICS INC.’s own tally for this item (“2. Ratification of the Selection of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2025”): 78,614,062 for, 3,591,463 against — passed, per its Form 8-K filed June 5, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025, was approved by stockholders.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 67 asset managers below reported 37,694,881 for, 135 against, 0 abstained, 64,819 not voted.

FOR

FOR: 37,694,881AGAINST: 135ABSTAIN: 0NOT VOTED: 64,819

Largest asset managers voting on “TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISC” at MYRIAD GENETICS INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	13,661,773	6	For
BlackRock	10,642,000	0	For
State Street	3,216,109	129	For
Fidelity	2,642,110	0	For
Dimensional	1,279,128	0	For
Charles Schwab	1,130,181	0	For
TIAA	1,075,090	0	For
Invesco	656,247	0	For
Elevation Series Trust	346,279	0	For
Goldman Sachs	253,198	0	For
Equitable	239,217	0	For
Jackson National	182,129	0	For
Columbia Threadneedle	180,059	0	For
JPMorgan	167,057	0	For
Global X	160,433	0	For
Prudential/PGIM	152,976	0	For
QUANTITATIVE MASTER SERIES LLC	150,778	0	For
Lincoln Financial	121,397	0	For
Northern Trust	111,886	0	For
BNY Mellon	98,811	0	For
Thrivent	93,170	0	For
Principal	88,419	0	For
TARGET PORTFOLIO TRUST	84,800	0	For
Voya	72,572	0	For
Direxion Shares ETF Trust	68,584	0	For

Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.

Largest MYRIAD GENETICS INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 92,200,000 shares outstanding at the time of that meeting.

Fund voting reports: top MYRIAD GENETICS INC. shareholders by shares voted on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, AS…”, 2024-2025
#	Asset manager	% of shares outstanding
1	Vanguard	14.82%
2	BlackRock	11.54%
3	State Street	3.49%
4	Fidelity	2.87%
5	Dimensional	1.39%
6	Charles Schwab	1.23%
7	TIAA	1.17%
8	Invesco	0.71%
9	Elevation Series Trust	0.38%
10	Goldman Sachs	0.27%

Institutional-manager reports: top MYRIAD GENETICS INC. shareholders by shares voted on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, AS…”, 2024-2025
#	Asset manager	% of shares outstanding
1	State Street	5.47%
2	DISCIPLINED GROWTH INVESTORS INC /MN	4.36%
3	Wellington	4.11%
4	GLENVIEW CAPITAL MANAGEMENT, LLC	4.04%
5	BlackRock	4.03%
6	EARNEST PARTNERS LLC	3.39%
7	DE Shaw	2.61%
8	Camber Capital Management LP	2.55%
9	GEODE CAPITAL MANAGEMENT, LLC	2.43%
10	Charles Schwab	1.29%

Reported MYRIAD GENETICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

MYRIAD GENETICS INC. holdings and ownership disclosed for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
BlackRock	16.77%	13F
Vanguard Group	11.57%	13F
State Street	5.71%	13F
GLENVIEW CAPITAL MANAGEMENT, LLC	5.36%	13G
Wellington Management	4.98%	13F
Millennium Management	4.50%	13F
Barclays PLC	4.27%	13G
D.E. Shaw	2.74%	13F
Dimensional Fund Advisors	2.40%	13F
Morgan Stanley	1.75%	13F

Percentages above are of 92,200,000 shares outstanding, as reported by MYRIAD GENETICS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from MYRIAD GENETICS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on October 14, 2026; a live search always shows the current data.

At MYRIAD GENETICS INC.'s shareholder meeting held June 5, 2025, in the 2024-2025 proxy season, 247 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 1,732 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, AS… — MYRIAD GENETICS INC.'s filing reports the proposal as approved, with 92% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: MYRIAD GENETICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 5, 2025.

MYRIAD GENETICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Download data (CSV): ballot items · votes by manager · column guide.